PLSE

PLSE

USD

Pulse Biosciences Inc Common Stock (DE)

$16.060-0.440 (-2.667%)

Цена в режиме реального времени

Healthcare
Medical Instruments & Supplies
Соединенные Штаты

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$16.500

Максимум

$16.770

Минимум

$15.800

Объем

0.11M

Фундаментальные показатели компании

Рыночная капитализация

1.1B

Отрасль

Medical Instruments & Supplies

Страна

United States

Статистические данные торговли

Средний объем

0.18M

Биржа

NCM

Валюта

USD

52-недельный диапазон

Минимум $13.766Текущая $16.060Максимум $25

Связанные новости

BusinessWire

Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study

First U.S. Surgical Treatments with PFA Clamp for Patients with Atrial Fibrillation During Concomitant Surgical Procedure Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology

Просмотреть больше
Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study
BusinessWire

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025

Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it

Просмотреть больше
Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025
BusinessWire

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Successfully treated atrial fibrillation (AF) in initial 30 patients with the nPulse™ Cardiac Surgical System Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology

Просмотреть больше
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
BusinessWire

Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced

Просмотреть больше
Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.